MCID: HYP014
MIFTS: 56

Hyperuricemia

Categories: Blood diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Hyperuricemia

MalaCards integrated aliases for Hyperuricemia:

Name: Hyperuricemia 12 76 55 44 15 73
Blood Urate Raized 12
Uricacidemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1920
MeSH 44 D033461
NCIt 50 C3961
SNOMED-CT 68 35885006
UMLS 73 C0740394

Summaries for Hyperuricemia

Disease Ontology : 12 An acquired metabolic disease that has material basis in an abnormally high level of uric acid in the blood.

MalaCards based summary : Hyperuricemia, also known as blood urate raized, is related to hyperuricemic nephropathy, familial juvenile, 1 and glycogen storage disease ia, and has symptoms including seizures, muscle weakness and fever. An important gene associated with Hyperuricemia is UMOD (Uromodulin), and among its related pathways/superpathways are Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds and Selenium Micronutrient Network. The drugs Allopurinol and Furosemide have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and endothelial, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 76 Hyperuricemia is an abnormally high level of uric acid in the blood. In the pH conditions of body fluid,... more...

Related Diseases for Hyperuricemia

Diseases in the Hyperuricemia family:

Hereditary Hyperuricemia

Diseases related to Hyperuricemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 190)
# Related Disease Score Top Affiliating Genes
1 hyperuricemic nephropathy, familial juvenile, 1 32.6 HPRT1 SLC22A12 UMOD
2 glycogen storage disease ia 32.3 G6PC INS
3 gout 31.6 ABCG2 HPRT1 SLC17A1 SLC17A3 SLC22A12 SLC2A9
4 kidney disease 30.6 CRP INS REN UMOD
5 chronic kidney failure 30.2 APOB CRP INS REN UMOD
6 nonalcoholic fatty liver disease 29.9 APOB CRP INS
7 coronary heart disease 1 29.9 APOB CRP INS
8 arteries, anomalies of 29.8 APOB CRP INS REN
9 nephrolithiasis 29.7 HPRT1 INS SLC22A12 SLC2A9 UMOD XDH
10 diabetes mellitus 29.6 ADRB3 APOB CRP INS REN
11 interstitial nephritis 29.6 CRP REN UMOD
12 diabetes mellitus, noninsulin-dependent 29.6 ADRB3 APOB CRP G6PC INS
13 ischemic heart disease 29.5 APOB CRP
14 lipid metabolism disorder 29.4 APOB CRP INS
15 end stage renal failure 29.3 APOB CRP UMOD
16 hypertension, essential 29.2 ADRB3 APOB CRP INS REN
17 arteriosclerosis 29.2 APOB CRP INS
18 vascular disease 29.1 APOB CRP INS REN XDH
19 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome 12.5
20 glomerulocystic kidney disease with hyperuricemia and isosthenuria 12.4
21 hereditary hyperuricemia 12.1
22 deafness hyperuricemia neurologic ataxia 12.1
23 hyperuricemia, infantile, with abnormal behavior and normal hypoxanthine guanine phosphoribosyltransferase 12.0
24 nephropathy familial with hyperuricemia 12.0
25 lesch-nyhan syndrome 12.0
26 hyperuricemic nephropathy, familial juvenile, 2 11.7
27 kelley-seegmiller syndrome 11.7
28 autosomal dominant tubulointerstitial kidney disease, ren-related 11.6
29 urate oxidase, pseudogene 11.3
30 fructose intolerance, hereditary 11.3
31 glycogen storage disease ib 11.1
32 autosomal dominant tubulointerstitial kidney disease 11.1
33 uric acid concentration, serum, quantitative trait locus 1 11.0
34 glycogen storage disease ic 11.0
35 osteodysplasia, familial, anderson type 11.0
36 phosphoribosylpyrophosphate synthetase superactivity 11.0
37 hyperuricemic nephropathy, familial juvenile, 4 11.0
38 familial primary hypomagnesemia with hypercalciuria and nephrocalcinosis 11.0
39 arthritis 10.3
40 atrial fibrillation 10.3
41 fatty liver disease 10.3
42 liver disease 10.3
43 heart disease 10.3
44 nephrolithiasis, uric acid 10.2 HPRT1 XDH
45 purine-pyrimidine metabolic disorder 10.2 HPRT1 XDH
46 postural hypotension 10.2 INS REN
47 adenine phosphoribosyltransferase deficiency 10.2 HPRT1 XDH
48 coronary artery anomaly 10.2
49 glycogen storage disease 10.2
50 fanconi-bickel syndrome 10.2 G6PC INS

Graphical network of the top 20 diseases related to Hyperuricemia:



Diseases related to Hyperuricemia

Symptoms & Phenotypes for Hyperuricemia

UMLS symptoms related to Hyperuricemia:


seizures, muscle weakness, fever, polydipsia, dyspnea, edema, cachexia, vertigo, headache, syncope, cyanosis, icterus, signs and symptoms, signs and symptoms, digestive, hot flushes

MGI Mouse Phenotypes related to Hyperuricemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.1 ABCG2 ADRB3 G6PC HPRT1 INS PFKM
2 homeostasis/metabolism MP:0005376 10.07 ABCG2 ADRB3 APOB CRP G6PC HPRT1
3 growth/size/body region MP:0005378 10.02 ADRB3 APOB G6PC HPRT1 INS REN
4 cardiovascular system MP:0005385 9.97 APOB CRP HPRT1 INS PFKM REN
5 adipose tissue MP:0005375 9.91 ABCG2 ADRB3 INS SLC2A9 UMOD XDH
6 immune system MP:0005387 9.85 ABCG2 APOB CRP HPRT1 INS PFKM
7 liver/biliary system MP:0005370 9.43 ABCG2 APOB G6PC HPRT1 INS SLC2A9
8 renal/urinary system MP:0005367 9.28 ABCG2 G6PC HPRT1 INS REN SLC22A12

Drugs & Therapeutics for Hyperuricemia

Drugs for Hyperuricemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Allopurinol Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 315-30-0 2094
2
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
3
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
4
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
5
Rasburicase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134774-45-1
6
Febuxostat Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 144060-53-7 134018
7
Probenecid Approved, Investigational Phase 4,Phase 2 57-66-9 4911
8
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 158781 130881
9
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
10
Colchicine Approved Phase 4,Phase 2 64-86-8 6167 2833
11
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
12
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
13
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
14
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
15
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 44475014
16
leucovorin Approved Phase 4 58-05-9 6006 143
17
Canagliflozin Approved Phase 4 842133-18-0
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
19
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
20
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
21
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
22
Uric Acid Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 69-93-2 1175
23
Cobalamin Experimental Phase 4 13408-78-1 6438156
24
Rosemary Experimental Phase 4
25 Antiprotozoal Agents Phase 4
26 Antiparasitic Agents Phase 4
27 Anthocyanidin Phase 4,Not Applicable
28
Procyanidin Phase 4 4852-22-6 147299
29 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Antioxidants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
31 Free Radical Scavengers Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
32 Anti-Infective Agents Phase 4,Phase 3,Phase 1
33 Proanthocyanidin Phase 4
34 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
36 Antihypertensive Agents Phase 4,Phase 2,Phase 3,Not Applicable
37 Sodium Chloride Symporter Inhibitors Phase 4,Phase 3
38 Sodium Potassium Chloride Symporter Inhibitors Phase 4
39 diuretics Phase 4,Phase 3
40 Natriuretic Agents Phase 4,Phase 3
41 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
42 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
43 Hormone Antagonists Phase 4,Phase 2,Phase 3
44 glucocorticoids Phase 4,Phase 2,Phase 3
45 Hormones Phase 4,Phase 2,Phase 3
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
47 Insulin, Globin Zinc Phase 4,Phase 3,Not Applicable
48 Renal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
49 insulin Phase 4,Phase 3,Not Applicable
50 Angiotensin Receptor Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 161)
# Name Status NCT ID Phase Drugs
1 Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines Unknown status NCT02797028 Phase 4 Allopurinol
2 Clinical Trial to Compare Effectiveness of Diuretics in Hemodialysis Patients With Residual Renal Function Unknown status NCT01977430 Phase 4 Hydrochlorothiazide and furosemide
3 Prednisone for Heart Failure Patients With Hyperuricemia Completed NCT00919243 Phase 4 prednisone;allopurinol
4 Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome Completed NCT00563771 Phase 4 Rasburicase
5 Zurig (Febuxostat) 40mg Efficacy and Safety Trial Completed NCT02600780 Phase 4 Febuxostat;Allopurinol
6 Rasburicase in Tumor Lysis Syndrome Completed NCT00302653 Phase 4 Rasburicase
7 Treatment of Hyperuricemia in Patients With Heart Failure Completed NCT00422318 Phase 4 Benzbromarone (drug)
8 Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome Completed NCT01654276 Phase 4 Febuxostat
9 Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Completed NCT00230217 Phase 4 Rasburicase (SR29142)
10 Allopurinol in Chronic Heart Failure Completed NCT00997542 Phase 4 Allopurinol;Placebo
11 Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers Completed NCT01907373 Phase 4 olmesartan medoxomil;olmesartan medoxomil+probenecid
12 Allopurinol Outcome Study Completed NCT01391325 Phase 4 Allopurinol
13 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
14 Fasturtec TLS Treatment / Prophylysis Completed NCT00651911 Phase 4 urate oxidase
15 Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels Completed NCT02060552 Phase 4 Diacerein;Colchicine;Febuxostat
16 Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout Completed NCT02500641 Phase 4 Febuxostat 80/120mg/day;Allopurinol 100 up to 600mg/day;Colchicine;Naproxen;Omeprazole
17 Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients Recruiting NCT03200210 Phase 4 Febuxostat;Placebo
18 Effect of Hyperuricaemia on Chronic Renal Disease Recruiting NCT03425708 Phase 4 20mg Febuxostat;40mg Febuxostat
19 The Intervention of Multi-vitamin With Minerals to Hyperuricemia Recruiting NCT03218709 Phase 4
20 The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF) Recruiting NCT03336203 Phase 4 Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet
21 Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction Active, not recruiting NCT03534037 Phase 4 Febuxostat 40 mg;Benzbromarone 50mg
22 The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics Active, not recruiting NCT02956278 Phase 4 Allopurinol
23 Pharmacogenetics of SGLT2 Inhibitors Enrolling by invitation NCT02462421 Phase 4 Canagliflozin
24 Allopurinol in Acute Coronary Syndrome Not yet recruiting NCT03745729 Phase 4 allopurinol sustained-release capsules;placebo capsules
25 the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia Terminated NCT02279342 Phase 4 Febuxostat
26 Long-term Prednisone Use for End-stage Heart Failure Unknown status NCT02282683 Phase 2, Phase 3 prednisone
27 The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients Unknown status NCT02563405 Phase 2, Phase 3 Doxazosin;Nifedipine
28 Role of Allopurinol on Oxidative Stress and Mitochondrial Alterations in Skeletal Muscle of Diabetic Patients Unknown status NCT02533648 Phase 3 2 capsules of allopurinol 150 mg daily for 3 month;2 capsules of lactose daily for 3 month
29 Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout Completed NCT03372200 Phase 3 FYU-981;Febuxostat
30 Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout Completed NCT03100318 Phase 3 FYU-981;Benzbromarone
31 Prednisone for Heart Failure Patients With Hyperuricemia Completed NCT02129764 Phase 2, Phase 3 Prednisone;Allopurinol
32 Study of FYU-981 in Hyperuricemia With or Without Gout Completed NCT03006445 Phase 3 FYU-981
33 Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia Completed NCT00921375 Phase 3 TULY
34 Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome Completed NCT00230178 Phase 3 Rasburicase (SR29142);Allopurinol
35 Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma Completed NCT00199043 Phase 3 Allopurinol;Rasburicase
36 Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout Completed NCT00325195 Phase 3
37 Efficacy and Safety of Oral Febuxostat in Participants With Gout Completed NCT00430248 Phase 3 Febuxostat;Febuxostat;Allopurinol
38 UAB Center of Research Translation (CORT) Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood Pressure Completed NCT02038179 Phase 2, Phase 3 Allopurinol;Placebo
39 Uric Acid and Hypertension in African Americans Completed NCT00241839 Phase 3 Allopurinol;Placebo;Chlorthalidone;Potassium chloride
40 Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout Completed NCT01356498 Phase 3
41 Molecular and Clinical Effects of Green Tea and Fermented Papaya Preparation on Diabetes and Cardiovascular Diseases Completed NCT01248143 Phase 2, Phase 3
42 Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients. Completed NCT02866214 Phase 2, Phase 3 Febuxostat;Placebo
43 Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 Completed NCT00175019 Phase 3 Febuxostat;Febuxostat;Allopurinol
44 Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES) Completed NCT01101035 Phase 3 Febuxostat;Allopurinol
45 BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada Completed NCT00272779 Phase 3 ATV;RTV;Tenofovi-Emtricitabine (TDF/FTC) tablet;LPV
46 Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer Completed NCT01234337 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo;Capecitabine
47 Rasburicase (Fasturtec) Registration Trial Terminated NCT00607152 Phase 3 Rasburicase;Allopurinol
48 Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout Unknown status NCT01519687 Phase 2 levotofisopam
49 A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product. Unknown status NCT00208000 Phase 2 Marine active
50 Hyperuricemia on Hypertension and Metabolic Syndrome Completed NCT01157936 Phase 2 Allopurinol

Search NIH Clinical Center for Hyperuricemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: hyperuricemia

Genetic Tests for Hyperuricemia

Anatomical Context for Hyperuricemia

MalaCards organs/tissues related to Hyperuricemia:

41
Kidney, Heart, Endothelial, Liver, Bone, Ovary, Myeloid

Publications for Hyperuricemia

Articles related to Hyperuricemia:

(show top 50) (show all 1177)
# Title Authors Year
1
Renal Effects of Hyperuricemia. ( 29393089 )
2018
2
Identification of new drug-like compounds from millets as Xanthine oxidoreductase inhibitors for treatment of Hyperuricemia: A molecular docking and simulation study. ( 29906649 )
2018
3
Treatment of Hyperuricemia in Chronic Kidney Disease. ( 29393124 )
2018
4
Hyperuricemia and Progression of Chronic Kidney Disease: Role of Phenotype Transition of Renal Tubular and Endothelial Cells. ( 29393109 )
2018
5
Hypouricemic Effects of Extracts From <i>Agrocybe aegerita</i> on Hyperuricemia Mice and Virtual Prediction of Bioactives by Molecular Docking. ( 29867500 )
2018
6
Value of three-dimensional speckle tracking echocardiography to assess left ventricular function in hyperuricemia patients. ( 29790109 )
2018
7
Significance of Hyperuricemia among Community-Based Screening Participants. ( 29393126 )
2018
8
Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample. ( 29790110 )
2018
9
Management of hyperuricemia and gout in obese patients undergoing bariatric surgery. ( 29888674 )
2018
10
Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia. ( 29318274 )
2018
11
Inhibiting PNP for the therapy of hyperuricemia in Lesch-Nyhan disease: preliminary in vitro studies with analogues of immucillin-G. ( 29869162 )
2018
12
Reduced peak stimulated growth hormone is associated with hyperuricemia in obese children and adolescents. ( 29785038 )
2018
13
Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. ( 29363262 )
2018
14
Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis. ( 29890945 )
2018
15
Cordycepin, a Characteristic Bioactive Constituent in<i>Cordyceps militaris</i>, Ameliorates Hyperuricemia through URAT1 in Hyperuricemic Mice. ( 29422889 )
2018
16
Dietary Potential Renal Acid Load Is Positively Associated with Serum Uric Acid and Odds of Hyperuricemia in the German Adult Population. ( 29378039 )
2018
17
Systemic Implications of Hyperuricemia. ( 29393131 )
2018
18
White blood cell count and the incidence of hyperuricemia: insights from a community-based study. ( 29936636 )
2018
19
What is the role of angiotensin receptor blockers in treatment of hyperuricemia coexisting with arterial hypertension? ( 29853726 )
2018
20
Identification of four genes as novel susceptibility loci for early-onset type 2 diabetes mellitus, metabolic syndrome, or hyperuricemia. ( 29930802 )
2018
21
Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in gout. ( 29799677 )
2018
22
Associations of hyperuricemia and obesity with remission of nonalcoholic fatty liver disease among Chinese men: A retrospective cohort study. ( 29415050 )
2018
23
Hyperuricemia enhances intracellular urate accumulation via down-regulation of cell-surface BCRP/ABCG2 expression in vascular endothelial cells. ( 29317200 )
2018
24
Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study). ( 29372470 )
2018
25
Genetic association and functional analysis of rs7903456 in FAM35A gene and hyperuricemia: a population based study. ( 29942023 )
2018
26
The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol. ( 29916098 )
2018
27
Physiology of Hyperuricemia and Urate-Lowering Treatments. ( 29904633 )
2018
28
Metabolomics approach by <sup>1</sup>H NMR spectroscopy of serum reveals progression axes for asymptomatic hyperuricemia and gout. ( 29871692 )
2018
29
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population. ( 29124443 )
2018
30
Hyperuricemia in Asian psoriatic arthritis patients. ( 29349920 )
2018
31
Hyperuricemia as a prognostic factor after acute coronary syndrome. ( 29407598 )
2018
32
Markers of Iron Status Are Associated with Risk of Hyperuricemia among Chinese Adults: Nationwide Population-Based Study. ( 29425155 )
2018
33
Compounds containing trace element copper or zinc exhibit as potent hyperuricemia inhibitors via xanthine oxidase inactivation. ( 29895374 )
2018
34
Rhabdomyolysis following status epilepticus with hyperuricemia: A case report and literature review. ( 29953009 )
2018
35
Hyperuricemia is associated with short-term outcomes in elderly patients with acute myocardial infarction. ( 29411328 )
2018
36
Hyperuricemia and dementia - a case-control study. ( 30170563 )
2018
37
Treating hyperuricemia related non-alcoholic fatty liver disease in rats with resveratrol. ( 30557833 )
2018
38
The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia. ( 30203749 )
2018
39
Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( 30246299 )
2018
40
Consumption of sugar sweetened beverages and dietary fructose in relation to risk of gout and hyperuricemia: a systematic review and meta-analysis. ( 30277800 )
2018
41
Recent  decreasing  trends  of  exposure  to  PCDDs/PCDFs/dioxin-like  PCBs  in  general  populations,  and  associations with  diabetes,  metabolic  syndrome,  and  gout/hyperuricemia. ( 30282853 )
2018
42
"Yellow-dragon Wonderful-seed Formula" for hyperuricemia in gout patients with dampness-heat pouring downward pattern: a pilot randomized controlled trial. ( 30314508 )
2018
43
Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two Phase II trials. ( 30334639 )
2018
44
White Powder Over Palm: An Unusual Presentation of Hyperuricemia in Polyarticular Gout. ( 30347956 )
2018
45
Hyperuricemia and Gout in Orthopaedics. ( 30376463 )
2018
46
Dietary factors and risk of gout and hyperuricemia: a meta-analysis and systematic review. ( 30485934 )
2018
47
A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands. ( 29721712 )
2018
48
Insights in Public Health: Hyperuricemia and Gout in Hawai'i. ( 29761031 )
2018
49
Plasma profiling of amino acids distinguishes acute gout from asymptomatic hyperuricemia. ( 30073607 )
2018
50
Improvement in Diagnosis and Treat-to-Target Management of Hyperuricemia in Gout: Results from the GEMA-2 Transversal Study on Practice. ( 29204859 )
2018

Variations for Hyperuricemia

Expression for Hyperuricemia

Search GEO for disease gene expression data for Hyperuricemia.

Pathways for Hyperuricemia

Pathways related to Hyperuricemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.86 ABCG2 G6PC SLC17A1 SLC17A3 SLC22A12 SLC2A9
2
Show member pathways
11.59 APOB CRP INS XDH
3 10.59 HPRT1 XDH
4 10.1 ABCG2 SLC17A1 SLC17A3 SLC22A12 SLC2A9

GO Terms for Hyperuricemia

Cellular components related to Hyperuricemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.17 ABCG2 PFKM SLC17A1 SLC17A3 SLC22A12 SLC2A9
2 endosome lumen GO:0031904 8.96 APOB INS

Biological processes related to Hyperuricemia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.83 ABCG2 SLC17A1 SLC17A3 SLC22A12 SLC2A9
2 glucose homeostasis GO:0042593 9.63 G6PC INS PFKM
3 drug transmembrane transport GO:0006855 9.49 ABCG2 SLC17A3
4 cholesterol efflux GO:0033344 9.48 ABCG2 APOB
5 glycogen catabolic process GO:0005980 9.4 G6PC PFKM
6 negative regulation of blood vessel diameter GO:0097756 9.37 CRP INS
7 phosphate ion transport GO:0006817 9.32 SLC17A1 SLC17A3
8 sialic acid transport GO:0015739 9.26 SLC17A1 SLC17A3
9 urate transport GO:0015747 9.26 SLC17A1 SLC17A3 SLC22A12 SLC2A9
10 glucose-6-phosphate transport GO:0015760 9.16 G6PC SLC17A3
11 urate metabolic process GO:0046415 9.1 ABCG2 G6PC SLC17A1 SLC17A3 SLC22A12 SLC2A9

Molecular functions related to Hyperuricemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.8 ABCG2 ADRB3 HPRT1 PFKM XDH
2 low-density lipoprotein particle receptor binding GO:0050750 9.37 APOB CRP
3 cholesterol transporter activity GO:0017127 9.32 ABCG2 APOB
4 insulin-like growth factor receptor binding GO:0005159 9.26 INS REN
5 drug transmembrane transporter activity GO:0015238 9.16 ABCG2 SLC17A3
6 sialic acid transmembrane transporter activity GO:0015136 8.96 SLC17A1 SLC17A3
7 urate transmembrane transporter activity GO:0015143 8.8 SLC17A3 SLC22A12 SLC2A9

Sources for Hyperuricemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....